



NDA 020496/S-026

SUPPLEMENT APPROVAL

Sanofi-aventis U.S. LLC
Attention: Payal Patel, Pharm.D.
Manager, U.S. Regulatory Affairs Marketed Products
55 Corporate Drive, Mailstop: 55C-205A
Bridgewater, NJ 08807

Dear Dr. Patel:

Please refer to your Supplemental New Drug Application (sNDA) dated January 21, 2013, received January 22, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Amaryl (glimepiride) tablets, 1 mg, 2 mg, and 4 mg.

We acknowledge receipt of your amendment dated April 2, 2013.

This “Changes Being Effected” supplemental new drug application proposes the following changes: a revision of the ADVERSE REACTIONS section, subsection 6.2 Postmarketing Experience, to add information pertaining to severe cases of thrombocytopenia and also thrombocytopenic purpura based on postmarketing experience.

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter for use as recommended in the enclosed, agreed-upon labeling text.

We note that your April 2, 2013, submission includes final printed labeling (FPL) for your package insert. We have not reviewed this FPL. You are responsible for assuring that the wording in this printed labeling is identical to that of the approved content of labeling in the structured product labeling (SPL) format.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Raymond Chiang, Regulatory Project Manager, at (301) 796-1940.

Sincerely,

{See appended electronic signature page}

Mary H. Parks, M.D.
Director
Division of Metabolism and Endocrinology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURE:
Package Insert

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MARY H PARKS
08/01/2013